United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - ciclopirox olamine (unii: 50md4sb4ap) (ciclopirox - unii:19w019zdrj) - ciclopirox 7.70 mg in 100 ml - ciclopirox olamine topical suspension usp, 0.77% (w/w) (lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum, and microsporum canis; cutaneous candidiasis (moniliasis) due to candida albicans; and tinea (pityriasis) versicolor due to malassezia furfur . ciclopirox olamine topical suspension usp, 0.77% (w/w) (lotion) is contraindicated in individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - ciclopirox olamine (unii: 50md4sb4ap) (ciclopirox - unii:19w019zdrj) - ciclopirox 7.7 mg in 1 g - ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum , and microsporum canis ; candidiasis (moniliasis) due to candida albicans ; and tinea (pityriasis) vesicolor due to malassezia furfur. ciclopirox olamine cream is contraindicated in individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - ciclopirox olamine (unii: 50md4sb4ap) (ciclopirox - unii:19w019zdrj) - ciclopirox olamine 7.7 mg in 1 g - ciclopirox olamine cream, usp is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum, and microsporum canis; candidiasis (moniliasis) due to candida albicans; and tinea (pityriasis) versicolor due to malassezia furfur. ciclopirox olamine cream, usp is contraindicated in individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

acella pharmaceuticals, llc - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 2.28 g in 1 ml - (to understand fully the indication for this product, please read the entireindications and usage section of the labeling.) ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis.therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis is not recommended. - ciclopirox topical solution, 8% (nail lacquer) should be used only under medical supervision as described above. - the effectiveness and safety of ciclopirox topical solution, 8% (nail lacquer) in the following populations has not been studied. the clinical trials with use of ciclopirox topical solution, 8% (nail lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were hiv seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. patients with severe plantar (moccasin) tinea pedis were also excluded. - the safety and efficacy of using ciclopirox topical solution, 8% (nail lacquer) daily for greater than 48 weeks have not been established. ciclopirox topical solution, 8% (nail lacquer) is contraindicated in individuals who have shown hypersensitivity to any of its components. based on the safety profile in adults, ciclopirox topical solution, 8% (nail lacquer) is considered safe for use in children twelve years and older. no clinical trials have been conducted in the pediatric population. clinical studies of ciclopirox topical solution, 8% (nail lacquer) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between elderly and younger patients.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% (nail lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to tricho-phyto rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. - ciclopirox topical solution, 8% (nail lacquer) should be used only under medica

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 80 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8%, (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. - ciclopirox topical solution, 8%, (nail lacquer), should be used only under me

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 80 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. - no studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. - ciclopirox topical solution, 8% (nail lacquer), should be used onl

United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 80 mg in 1 ml - (to understand fully the indication for this product, please read the entire indications and usage section of the labeling.) ciclopirox topical solution, 8% as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to trichophyton rubrum . the comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. the results of use of ciclopirox topical solution, 8% in treatment of onychomycosis of the toenail without lunula involvement were obtained from two double-blind, placebo-controlled studies conducted in the united states. in these studies, patients with onychomycosis of the great toenails without lunula involvement were treated with ciclopirox topical solution, 8% in conjun

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 7.70 mg in 1 g - superficial dermotophyte infections - ciclopirox gel 0.77% is indicated for the topical treatment of interdigital tinea pedis and tinea corporis due to trichophyton   rubrum , trichophyton   mentagrophytes , epidermophyton   floccosum . seborrheic dermatitis - ciclopirox gel 0.77% is indicated for the topical treatment of seborrheic dermatitis of the scalp. ciclopirox gel 0.77% is contraindicated in individuals who have shown hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - ciclopirox (unii: 19w019zdrj) (ciclopirox - unii:19w019zdrj) - ciclopirox 7.7 mg in 1 g - not for use in eyes. rx only superficial dermatophyte infections ciclopirox gel is indicated for the topical treatment of interdigital tinea pedis and tinea corporis due to trichophyton rubrum, trichophyton mentagrophytes, or epidermophyton floccosum . seborrheic dermatitis ciclopirox gel is indicated for the topical treatment of seborrheic dermatitis of the scalp. ciclopirox gel is contraindicated in individuals who have shown hypersensitivity to any of its components.